Substudy 03C: A Study of Combination Therapies in Participants with Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Trial Identifier: 3475-03C
Sponsor: MSD
Collaborator:
Exelixis, Inc.
Start Date: July 2025
Primary Completion Date: October 2031
Study Completion Date: October 2031
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary - English

Trial Locations

Country Location
France, Haute-Garonne Toulouse, Haute-Garonne, France, 31059
France, Ile-de-France Villejuif, Ile-de-France, France, 94805
France, Ille-et-Vilaine Rennes, Ille-et-Vilaine, France, 35042
France, Meurthe-et-Moselle Vandoeuvre Les Nancy, Meurthe-et-Moselle, France, 54513
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Petah-Tikva, N/A, Israel, 4941492
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Israel, N/A Tel Aviv, N/A, Israel, 6423906
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
Poland, Kujawsko-pomorskie Bydgoszcz, Kujawsko-pomorskie, Poland, 85-796
Poland, Pomorskie Gdansk, Pomorskie, Poland, 80-214
Spain, Barcelona Barcelona, Spain, 08035
Spain, Madrid, Comunidad de Madrid, Madrid, Comunidad de, Spain, 28034
United Kingdom, Edinburgh, City of Edinburgh, Edinburgh, City of, United Kingdom, EH42XU
United Kingdom, London, City of London, London, City of, United Kingdom, EC1A7BE
United Kingdom, Manchester Manchester, United Kingdom, M20 4BX
United States, CA San Francisco, CA, United States, 94158
United States, NC Durham, NC, United States, 27710
United States, NY Mineola, NY, United States, 11501
United States, NY New York, NY, United States, 10065
United States, NY New York, NY, United States, 10016